Genmab: strong Darzalex sales

(CercleFinance.com) - The share of Danish biotech group Genmab is up nearly 2% in Copenhagen on Wednesday after announcing 2019 sales figures for its anticancer drug Darzalex, a drug to treat multiple myeloma that it discovered, but which is now marketed by a Johnson & Johnson subsidiary.


Genmab says annual intravenous sales reached the 3 billion dollar threshold last year, triggering a milestone payment of 150 million dollars under the license agreement reached with Janssen, J&J's biopharmaceutical subsidiary.

The biotechnology company - which is now trying to develop its own drug portfolio - said that it is "extremely satisfied" with the sales growth posted by Darzalex.

Just over an hour before close, the share is up nearly 2% at 1,548.5 Danish kronor, making it one of the biggest winners in the OMXC25 index.


Copyright (c) 2020 CercleFinance.com. All rights reserved.